Knight Therapeutics (TSE:GUD)
TSX:GUD
Want to see TSE:GUD full AI Analyst Report?
Earnings Data
Report Date
Aug 06, 2026Before Open (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
0.02Last Year’s EPS
-0.13Same Quarter Last Year
Strong Buy
Based on 4 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed strong operational and financial momentum—record quarterly revenues and adjusted EBITDA, improved gross margin, a stronger balance sheet and an active launch and BD pipeline—supported by raised 2026 guidance. Key challenges include a withdrawal and delayed resubmission of Qelbree's Health Canada filing due to manufacturing changes, a meaningful YoY increase in operating expenses, a small Q1 net loss from investment revaluations, and medium-term risks from potential generic competition and Argentina hyperinflation exposure. Overall, the positive financial results, strengthened liquidity and well-filled launch pipeline materially outweigh the identifiable near-term execution and macro risks.Company Guidance
Record Revenue Growth
Reported record Q1 2026 revenues of $148 million, an increase of approximately $59.6–$60 million year-over-year (about +68–69% YoY). Growth drivers included incremental revenues from the Sumitomo and Paladin portfolios, promoted products and customer purchasing patterns.
Record Adjusted EBITDA and Per-Share Improvement
Adjusted EBITDA was a record $28 million in Q1 2026, up $15.8 million or +130% YoY. Adjusted EBITDA per share was $0.28, up approximately +133% YoY.
Strong Gross Margin
Adjusted gross margin of $70.6 million, representing 48% of revenues (vs. $40.9 million or 47% in prior-year period); margin improvement driven by revenue growth.
Improved Liquidity and Balance Sheet
Operating cash inflows of $41 million in the quarter; cash and marketable securities of $127 million at quarter-end; net cash position improved from $27 million at end of 2025 to $69 million at the end of Q1 2026. Debt approximately $58 million and debt to adjusted EBITDA leverage ratio under 0.7x; $40 million of $60 million withdrawn on the revolving facility has already been repaid.
Substantial Regulatory Progress and Launches
Submitted Niktimvo for approval in Brazil and Minjuvi for follicular lymphoma in Argentina and Mexico; obtained Brazilian approval for Minjuvi's second indication (follicular lymphoma). Executed four launches so far in 2026 (Minjuvi FL in Brazil, Pemazyre in Argentina, Akynzeo in Paraguay and Bapocil in Colombia).
Robust Launch Pipeline and Medium-Term Opportunity
Company has completed ~15 launches over the last 2 years and expects ~10 launches in 2026. Management estimates a ~$200 million peak revenue opportunity in the pipeline, with ~$40 million (20% of the $200M) already realized on a trailing 12-month basis.
Promoted & Strategic Product Contribution
Of incremental Q1 revenues, mature products (Paladin & Sumitomo) contributed ~$17 million, launch-pipeline products ~$13 million and strategic products grew by ~$28 million; Ambisome contributed an incremental ~$14 million.
Share Buyback (NCIB) Activity
Purchased 1.3 million common shares in the quarter at an average price of $6.22 for aggregate cash consideration of $8.2 million; 2 million shares purchased to date under the NCIB with capacity to buy an additional 4.2 million shares until August 2026.
Raised Financial Outlook for Fiscal 2026
Updated guidance expects 2026 revenues of $510–$525 million and adjusted EBITDA of approximately 15% of revenues. Management cites better performance across promoted products and improved forecasted LatAm currencies as drivers.
Healthy Business Development Pipeline
Management reports continued, healthy deal flow for in-licensing and acquisitions; excluding the two large portfolio purchases last year, the company averages ~3 product additions per year historically.
TSE:GUD Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
TSE:GUD Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 07, 2026 | C$7.51 | C$8.35 | +11.19% |
Mar 19, 2026 | C$6.17 | C$6.30 | +2.11% |
Nov 06, 2025 | C$5.84 | C$6.07 | +3.94% |
Aug 07, 2025 | C$6.29 | C$6.40 | +1.75% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Knight Therapeutics (TSE:GUD) report earnings?
Knight Therapeutics (TSE:GUD) is schdueled to report earning on Aug 06, 2026, Before Open (Confirmed).
What is Knight Therapeutics (TSE:GUD) earnings time?
Knight Therapeutics (TSE:GUD) earnings time is at Aug 06, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is TSE:GUD EPS forecast?
TSE:GUD EPS forecast for the fiscal quarter 2026 (Q2) is 0.02.